Dipeptidyl peptidase-4 (DPP-4) inhibitors prior authorization
Customize your policy alerts
Sign up for allcareadvantage Policy 024.2 alerts
Get alerted when Policy 024.2 changes without checking for updates manually.
Monitor payer policy activity
Defines prior authorization coverage rules for non-preferred and non-formulary dipeptidyl peptidase-4 (DPP-4) inhibitors for members with type 2 diabetes mellitus, including combination agents containing metformin and DPP-4 inhibitors.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.